Moomoo AI 已提取核心信息
On December 31, 2023, Armistice Capital, LLC, an investment adviser, and Steven Boyd, its managing member, filed an amended Schedule 13G/A with the SEC, disclosing a 3.80% ownership stake in Biora Therapeutics, Inc., amounting to 1,074,895 shares. This filing indicates that Armistice Capital, LLC has shared voting and dispositive power over the shares, which are held by Armistice Capital Master Fund Ltd. The filing also notes that the Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The shares represent a stake in the company based on 28,284,172 shares outstanding as of December 22, 2023. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain investment advisers, and Rule 13d-1(g), pertaining to parent holding companies or control persons. The filing was completed on February 14, 2024, and includes a certification by Steven Boyd that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Biora Therapeutics.
On December 31, 2023, Armistice Capital, LLC, an investment adviser, and Steven Boyd, its managing member, filed an amended Schedule 13G/A with the SEC, disclosing a 3.80% ownership stake in Biora Therapeutics, Inc., amounting to 1,074,895 shares. This filing indicates that Armistice Capital, LLC has shared voting and dispositive power over the shares, which are held by Armistice Capital Master Fund Ltd. The filing also notes that the Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The shares represent a stake in the company based on 28,284,172 shares outstanding as of December 22, 2023. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain investment advisers, and Rule 13d-1(g), pertaining to parent holding companies or control persons. The filing was completed on February 14, 2024, and includes a certification by Steven Boyd that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Biora Therapeutics.
2023年12月31日，投资顾问停战资本有限责任公司及其管理成员史蒂芬·博伊德向美国证券交易委员会提交了经修订的附表13G/A，披露了Biora Therapeutics, Inc. 3.80％的所有权，总额为1,074,895股。该文件表明，Armistice Capital, LLC对停战资本主基金有限公司持有的股票拥有共同的投票权和处置权。该文件还指出，由于与停战资本签订了投资管理协议，主基金宣布放弃对证券的实益所有权。根据截至2023年12月22日的已发行28,284,172股股份，这些股票代表该公司的股份。该文件是根据适用于某些投资顾问的1934年《证券交易法》第13d-1（b）条和与母控公司或控制人有关的第13d-1（g）条提交的。该文件于2024年2月14日完成，其中包括史蒂芬·博伊德的认证，即这些股票是在正常业务过程中收购的，不是为了改变或影响Biora Therapeutics的控制权。
2023年12月31日，投资顾问停战资本有限责任公司及其管理成员史蒂芬·博伊德向美国证券交易委员会提交了经修订的附表13G/A，披露了Biora Therapeutics, Inc. 3.80％的所有权，总额为1,074,895股。该文件表明，Armistice Capital, LLC对停战资本主基金有限公司持有的股票拥有共同的投票权和处置权。该文件还指出，由于与停战资本签订了投资管理协议，主基金宣布放弃对证券的实益所有权。根据截至2023年12月22日的已发行28,284,172股股份，这些股票代表该公司的股份。该文件是根据适用于某些投资顾问的1934年《证券交易法》第13d-1（b）条和与母控公司或控制人有关的第13d-1（g）条提交的。该文件于2024年2月14日完成，其中包括史蒂芬·博伊德的认证，即这些股票是在正常业务过程中收购的，不是为了改变或影响Biora Therapeutics的控制权。
有用
没用